• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Design, Development and Therapy >Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19
【24h】

Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19

机译：血浆丸，抗ACE2和抗FCγRII单克隆抗体：对Covid-19严重病例的可能治疗方法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In March 2020, the WHO declared the COVID-19 disease as a pandemic disease. There have been studies on the COVID-19 to find a certain treatment, but yet, there is no certain cure. In this article, we present a possible way to treat severe cases of COVID-19. Based on the previous studies, there are similarities between the spike antigens of SARS-CoV and SARS-CoV-2 viruses. It is expected that these similarities (structural and affinity to the receptor of ACE2) can lead to the same pathophysiological activity of the virus by the use of ACE2 and FcγRII (the antibody-dependent enhancement mechanism). Therefore, we propose a way of washing out (by plasmapheresis) the possible antibodies against the spike protein of the virus out of patients’ plasma to stop the antibody-dependent enhancement (ADE)-mediated infection of the immune system cells at the first phase of the treatment and simultaneous use of the anti-ACE2 with anti-FcγRII monoclonal antibodies at the second phase. We propose these procedures for the patients that have no significant response for typical anti-viral, ARDS and conservative therapies, and the disease persists or progresses despite sufficient therapies.
机译：2020年3月，谁宣布了Covid-19疾病作为大流行病。有关于Covid-19的研究，找到了一定的治疗方法，但尚未确定。在本文中，我们提出了治疗Covid-19严重案例的可能方法。基于先前的研究，SARS-COV和SARS-COV-2病毒的尖峰抗原之间存在相似之处。预期这些相似性（对ACE2的受体的结构和亲和力）可以通过使用ACE2和FCγRII（抗体依赖性增强机制）来导致病毒的相同病理学活性。因此，我们提出了一种洗涤（通过血浆粉碎）可能抗体的刺激蛋白质的刺激患者的血浆，以阻止抗体依赖性增强（ADE）介断在第一阶段的免疫系统细胞感染对第二阶段抗FCγRII单克隆抗体的治疗及同时使用抗αCE2。我们为典型的抗病毒，ARDS和保守疗法没有显着反应的患者提出了这些程序，并且尽管有足够的疗法，这种疾病仍然存在或进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号